August 2012
-
MannKind Corporation will develop a dry powder formulation of Thirona Bio’s FBM5712 ALK-5 kinase inhibitor, the companies have announced. The deal gives MannKind the option to license the compound for the treatment of fibrotic diseases in the lung and… Read more . . .
-
Nuance Pharma will pay $25 million in cash, plus equity in its parent company Nuance Biotech valued at $15 million, as well as potential milestone payments worth up to $179 million to Verona Pharma for… Read more . . .
-
Proveris Scientific, a specialist in aerosol drug delivery testing, announced that it has hired engineer Prateek Nath to “to design and build a wide variety of research-grade prototypes and run experiments on these prototypes to… Read more . . .
-
Nuformix said that it has received a Notice of Allowance for US Patent Application No. 17/051,592 titled, “Crystalline Tranilast Salts and Their Pharmaceutical Use.” The company has already been granted one patent covering crystalline forms… Read more . . .
-
Noveome Biotherapeutics said that a Phase 1 safety study of its intranasal ST266 secretome in glaucoma suspect patients demonstrated no serious adverse events at doses up to 400 µL per day over 28 days. The… Read more . . .
-
The FDA is touting its June 1, 2021 approval of Sandoz’s ANDA for an albuterol sulfate MDI for the treatment of asthma, saying, “The FDA recognizes the increased demand for certain products during the COVID-19… Read more . . .
-
Lupin has announced the US launch of an authorized generic version of Sunovion’s Brovana arformoterol tartrate inhalation solution for the treatment of COPD. The FDA tentatively approved the company’s ANDA for the inhalation solution in… Read more . . .
-
Evoke Pharma said that the United States Patent and Trademark Office (USPTO) has issued US patent No. 11,020,361 (“Nasal Formulations of Metoclopramide”) covering methods of use for Gimoti metoclopramide nasal spray for the treatment of gastroparesis… Read more . . .
-
According to Liquidia, the FDA has accepted the company’s resubmitted NDA for LIQ861 treprostinil DPI for the treatment of pulmonary arterial hypertension and has set a PDUFA goal date of November 7, 2021. Liquidia initially… Read more . . .
-
Aerosol testing specialist Proveris Scientific has named Maria L. Smith as Director, Application and Business Development for Proveris Laboratories. Smith has extensive experience in OINDP spray characterization, first at DPT Laboratories and then at Renaissance Lakewood.… Read more . . .
Featured event:
5th Annual Inhaled & Nasal Biologics | DNA Forum
5th Annual Inhaled & Nasal Biologics | DNA Forum
24th-25th September 2026, Cambridge, UK
Join us for a ground-breaking and insightful forum: Two days of cutting-edge talks and networking opportunities in this complex area of drug and vaccine development.
With renowned industry leaders who will share their insights and real-world case studies, our speakers will explore innovative formulation and delivery technologies and the rationale behind overcoming development challenges. Don’t miss out on this opportunity to learn more about key topics shaping the future of inhaled therapeutics.
Get online to see speakers announced so far. Registration is live – save your seat now!
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
No events are found.